1. Home
  2. LEGN vs PIPR Comparison

LEGN vs PIPR Comparison

Compare LEGN & PIPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LEGN
  • PIPR
  • Stock Information
  • Founded
  • LEGN 2014
  • PIPR 1895
  • Country
  • LEGN United States
  • PIPR United States
  • Employees
  • LEGN N/A
  • PIPR N/A
  • Industry
  • LEGN Biotechnology: Pharmaceutical Preparations
  • PIPR Investment Bankers/Brokers/Service
  • Sector
  • LEGN Health Care
  • PIPR Finance
  • Exchange
  • LEGN Nasdaq
  • PIPR Nasdaq
  • Market Cap
  • LEGN 5.9B
  • PIPR 6.2B
  • IPO Year
  • LEGN 2020
  • PIPR N/A
  • Fundamental
  • Price
  • LEGN $29.60
  • PIPR $316.87
  • Analyst Decision
  • LEGN Strong Buy
  • PIPR Buy
  • Analyst Count
  • LEGN 13
  • PIPR 3
  • Target Price
  • LEGN $72.92
  • PIPR $362.50
  • AVG Volume (30 Days)
  • LEGN 1.3M
  • PIPR 156.0K
  • Earning Date
  • LEGN 11-12-2025
  • PIPR 10-31-2025
  • Dividend Yield
  • LEGN N/A
  • PIPR 1.82%
  • EPS Growth
  • LEGN N/A
  • PIPR 42.49
  • EPS
  • LEGN N/A
  • PIPR 13.30
  • Revenue
  • LEGN $909,045,000.00
  • PIPR $1,717,433,000.00
  • Revenue This Year
  • LEGN $68.68
  • PIPR $17.04
  • Revenue Next Year
  • LEGN $48.49
  • PIPR $14.67
  • P/E Ratio
  • LEGN N/A
  • PIPR $23.90
  • Revenue Growth
  • LEGN 74.75
  • PIPR 13.46
  • 52 Week Low
  • LEGN $27.34
  • PIPR $202.91
  • 52 Week High
  • LEGN $45.30
  • PIPR $374.77
  • Technical
  • Relative Strength Index (RSI)
  • LEGN 30.03
  • PIPR 40.60
  • Support Level
  • LEGN $29.92
  • PIPR $319.95
  • Resistance Level
  • LEGN $33.50
  • PIPR $342.61
  • Average True Range (ATR)
  • LEGN 1.31
  • PIPR 12.66
  • MACD
  • LEGN -0.21
  • PIPR -1.23
  • Stochastic Oscillator
  • LEGN 7.78
  • PIPR 24.02

About LEGN Legend Biotech Corporation

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

About PIPR Piper Sandler Companies

Piper Sandler Cos is an investment bank and institutional securities firm, serving the needs of corporations, private equity groups, public entities, non-profit entities and institutional investors in the United States (U.S.) and internationally. The company provides a broad set of products and services, including financial advisory services; equity and debt capital markets products; public finance services; institutional brokerage services; fundamental equity and macro research services; fixed income services; and alternative asset management strategies. It generates maximum revenue from Advisory services followed by Equity financing.

Share on Social Networks: